{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2005"],"condition":["Colorectal Cancer","Colorectal Neoplasms"],"disease":["Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2200534"],"location":["Bulgaria"],"study_start_month":["8"],"keyword":["Capecitabine"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer","description":"This study will evaluate the safety and tolerability of capecitabine (Xeloda) in participants who have undergone surgery for colon cancer. Oral Xeloda will be administered twice daily in 3-week cycles for a total of up to 8 cycles. The anticipated time on study treatment is 24 weeks, and the target sample size is 70 individuals.","dates":{"creation":"2005-08-15"},"accession":"2200534","cross_references":{"ClinicalTrials___gov":["NCT02581423"]}}